A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway

Abstract Background Anti-angiogenic therapy has been widely applied to the clinical treatment of malignant tumors. However, the efficacy of such treatments has been called into question, especially in triple-negative breast cancer (TNBC). Bevacizumab, the first anti-angiogenic agent approved by FDA,...

Full description

Bibliographic Details
Main Authors: Wei Xie, Huijie Zhao, Fengxian Wang, Yiyun Wang, Yuan He, Tong Wang, Kunchi Zhang, Hao Yang, Zhaoli Zhou, Haibin Shi, Jin Wang, Gang Huang
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13046-020-01800-x